180 related articles for article (PubMed ID: 38235318)
21. Combination of AKT1 and CDH1 mutations predicts primary resistance to immunotherapy in dMMR/MSI-H gastrointestinal cancer.
Wang Z; Zhang Q; Qi C; Bai Y; Zhao F; Chen H; Li Z; Wang X; Chen M; Gong J; Peng Z; Zhang X; Cai J; Chen S; Zhao X; Shen L; Li J
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35705314
[TBL] [Abstract][Full Text] [Related]
22. Comprehensive assessment of PD-L1 expression, tumor mutational burden and oncogenic driver alterations in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Yoh K; Matsumoto S; Furuya N; Nishino K; Miyamoto S; Oizumi S; Okamoto N; Itani H; Kuyama S; Nakamura A; Nishi K; Fukuda I; Tsuta K; Hayashi Y; Motoi N; Ishii G; Goto K
Lung Cancer; 2021 Sep; 159():128-134. PubMed ID: 34333203
[TBL] [Abstract][Full Text] [Related]
23. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.
Luchini C; Bibeau F; Ligtenberg MJL; Singh N; Nottegar A; Bosse T; Miller R; Riaz N; Douillard JY; Andre F; Scarpa A
Ann Oncol; 2019 Aug; 30(8):1232-1243. PubMed ID: 31056702
[TBL] [Abstract][Full Text] [Related]
24. A pan-cancer analysis of PD-L1 immunohistochemistry and gene amplification, tumor mutation burden and microsatellite instability in 48,782 cases.
Huang RSP; Haberberger J; Severson E; Duncan DL; Hemmerich A; Edgerly C; Ferguson NL; Williams E; Elvin J; Vergilio JA; Killian JK; Lin DI; Tse J; Hiemenz M; Owens C; Danziger N; Hegde PS; Venstrom J; Alexander B; Ross JS; Ramkissoon SH
Mod Pathol; 2021 Feb; 34(2):252-263. PubMed ID: 32884129
[TBL] [Abstract][Full Text] [Related]
25. Beyond Tumor PD-L1: Emerging Genomic Biomarkers for Checkpoint Inhibitor Immunotherapy.
Lagos GG; Izar B; Rizvi NA
Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-11. PubMed ID: 32315237
[TBL] [Abstract][Full Text] [Related]
26. Cancer neoantigens as potential targets for immunotherapy.
Ma W; Pham B; Li T
Clin Exp Metastasis; 2022 Feb; 39(1):51-60. PubMed ID: 33950415
[TBL] [Abstract][Full Text] [Related]
27. Identification and validation of a PD-L1-related signature from mass spectrometry in gastric cancer.
Chen X; Mao D; Li D; Li W; Wei H; Deng C; Chen H; Zhang C
J Cancer Res Clin Oncol; 2023 Aug; 149(9):5871-5884. PubMed ID: 36592213
[TBL] [Abstract][Full Text] [Related]
28. The association of genomic lesions and PD-1/PD-L1 expression in resected triple-negative breast cancers.
Barrett MT; Lenkiewicz E; Malasi S; Basu A; Yearley JH; Annamalai L; McCullough AE; Kosiorek HE; Narang P; Wilson Sayres MA; Chen M; Anderson KS; Pockaj BA
Breast Cancer Res; 2018 Jul; 20(1):71. PubMed ID: 29996881
[TBL] [Abstract][Full Text] [Related]
29. A Novel Oncogenic Role of FDX1 in Human Melanoma Related to PD-L1 Immune Checkpoint.
Lu H; Liang J; He X; Ye H; Ruan C; Shao H; Zhang R; Li Y
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298135
[TBL] [Abstract][Full Text] [Related]
30. Baseline extracellular vesicle TGF-β is a predictive biomarker for response to immune checkpoint inhibitors and survival in non-small cell lung cancer.
de Miguel-Perez D; Russo A; Gunasekaran M; Buemi F; Hester L; Fan X; Carter-Cooper BA; Lapidus RG; Peleg A; Arroyo-Hernández M; Cardona AF; Naing A; Hirsch FR; Mack PC; Kaushal S; Serrano MJ; Adamo V; Arrieta O; Rolfo C
Cancer; 2023 Feb; 129(4):521-530. PubMed ID: 36484171
[TBL] [Abstract][Full Text] [Related]
31. Profiles of PD-1, PD-L1, PD-L2 in Gastric Cancer and Their Relation with Mutation, Immune Infiltration, and Survival.
Liu J; Li H; Sun L; Yuan Y; Xing C
Biomed Res Int; 2020; 2020():2496582. PubMed ID: 32596285
[TBL] [Abstract][Full Text] [Related]
32. Prognostic perspectives of PD-L1 combined with tumor-infiltrating lymphocytes, Epstein-Barr virus, and microsatellite instability in gastric carcinomas.
Choi E; Chang MS; Byeon SJ; Jin H; Jung KC; Kim H; Lee KL; Kim W; Park JH; Kim KH; Kim JS; Choi IS; Han DS; Ahn HS; Heo SC
Diagn Pathol; 2020 Jun; 15(1):69. PubMed ID: 32498695
[TBL] [Abstract][Full Text] [Related]
33. Biomarkers predicting clinical outcomes in nasopharyngeal cancer patients receiving immune checkpoint inhibitors: A systematic review and meta-analysis.
Qian X; Chen H; Tao Y
Front Immunol; 2023; 14():1146898. PubMed ID: 37063822
[TBL] [Abstract][Full Text] [Related]
34. MET is overexpressed in microsatellite instability-high gastric carcinoma.
Sim J; Heo YJ; Bae H; Shin HC; Kim B; Cho J; Kim ST; Lee J; Kang WK; Kim KM
Pathol Res Pract; 2019 Mar; 215(3):433-438. PubMed ID: 30455128
[TBL] [Abstract][Full Text] [Related]
35. [Expert Consensus on Tumor Mutational Burden for Immunotherapy in Lung Cancer].
;
Zhongguo Fei Ai Za Zhi; 2021 Nov; 24(11):743-752. PubMed ID: 34802204
[TBL] [Abstract][Full Text] [Related]
36. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
37. Computed tomography-detected extramural venous invasion-related gene signature: a potential negative biomarker of immune checkpoint inhibitor treatment in patients with gastric cancer.
Yang H; Gou X; Feng C; Zhang Y; Chai F; Hong N; Ye Y; Wang Y; Gao B; Cheng J
J Transl Med; 2023 Jan; 21(1):4. PubMed ID: 36604653
[TBL] [Abstract][Full Text] [Related]
38. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
39. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
40. Genomic and transcriptomic analysis of MSI-H colorectal cancer patients with targetable alterations identifies clinical implications for immunotherapy.
Hua H; He W; Chen N; He Y; Wu G; Ye F; Zhou X; Li Y; Ding Y; Zhong W; Teng L; Jiang W; Sheng Q
Front Immunol; 2022; 13():974793. PubMed ID: 36700211
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]